About: Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19

Facets (new session)
Description
Metadata
Settings
- owl:sameAs
- Inference Rule:

About: Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19 Goto Sponge NotDistinct Permalink

An Entity of Type : schema:ScholarlyArticle, within Data Space : covidontheweb.inria.fr associated with source document(s)

Attributes	Values
type	Academic Article research paper schema:ScholarlyArticle
isDefinedBy	Covid-on-the-Web dataset
has title	Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19
Creator	Liu, Zhengwen Chen, Yuting Fan, Xiude Han, Qunying Sun, Jingkang Wang, Xiaoyun
Source	Medline; PMC
abstract	Coronavirus Disease 2019 (COVID-19), caused by severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), is spreading worldwide. Antiviral therapy is the most important treatment for COVID-19. Among the drugs under investigation, anti-malarials, chloroquine (CQ) and hydroxychloroquine (HCQ), are being repurposed as treatment for COVID-19. CQ/HCQ were shown to prevent receptor recognition by coronaviruses, inhibit endosome acidification, which interferes with membrane fusion, and exhibit immunomodulatory activity. These multiple mechanisms may work together to exert a therapeutic effect on COVID-19. A number of in vitro studies revealed inhibitory effects of CQ/HCQ on various coronaviruses, including SARS-CoV-2 although conflicting results exist. Several clinical studies showed that CQ/HCQ alone or in combination with a macrolide may alleviate the clinical symptoms of COVID-19, promote viral conversion, and delay disease progression, with less serious adverse effects. However, recent studies indicated that the use of CQ/HCQ, alone or in combination with a macrolide, did not show any favorable effect on patients with COVID-19. Adverse effects, including prolonged QT interval after taking CQ/HCQ, may develop in COVID-19 patients. Therefore, current data are not sufficient enough to support the use of CQ/HCQ as therapies for COVID-19 and increasing caution should be taken about the application of CQ/HCQ in COVID-19 before conclusive findings are obtained by well-designed, multi-center, randomized, controlled studies.
has issue date	2020-06-21(xsd:dateTime)
bibo:doi	10.1080/00325481.2020.1778982
bibo:pmid	32496926
has license	no-cc
sha1sum (hex)	72c361de577bee73ad79021301c10619f3558f34
schema:url	https://doi.org/10.1080/00325481.2020.1778982
resource representing a document's title	Advances in the use of chloroquine and hydroxychloroquine for the treatment of COVID-19
has PubMed Central identifier	PMC7441788
has PubMed identifier	32496926
schema:publication	Postgraduate medicine
resource representing a document's body	covid:72c361de577bee73ad79021301c10619f3558f34#body_text
is schema:about of	named entity 'mechanisms' named entity 'hydroxychloroquine' named entity 'COVID-19' named entity 'CORONAVIRUS DISEASE 2019' named entity 'EXHIBIT' named entity 'THERAPEUTIC EFFECT' named entity 'CLINICAL STUDIES' named entity 'INTERFERES WITH' named entity 'coronaviruses' named entity 'promote' named entity 'macrolide' named entity 'COVID-19' named entity 'clinical studies' named entity 'acidification' named entity 'inhibit' named entity 'membrane fusion' named entity 'However' named entity 'COVID-19' named entity 'effects' named entity 'endosome' named entity 'severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2)' named entity 'SARS-CoV-2' named entity 'inhibitory' named entity 'combination' named entity 'immunomodulatory' named entity 'coronaviruses' named entity 'MAPK' named entity 'virus' named entity 'gangliosides' named entity 'HCQ' named entity 'HCQ' named entity 'cell culture' named entity 'HCoV-OC43' named entity 'COVID' named entity 'ELs' named entity 'kidney' named entity 'inflammatory factors' named entity 'macrolide' named entity 'leukopenia' named entity 'HCQ' named entity 'SARS-CoV-2' named entity 'COVID' named entity '19.25' named entity 'nucleic acid' named entity 'COVID' named entity 'protein' named entity 'IL-6' named entity 'HCQ' named entity 'HCQ' named entity 'proteases' named entity 'analog' named entity 'host defense' named entity 'HCQ' named entity 'Ebola' named entity 'protein' named entity 'SARS-CoV-2' named entity 'vaccines' named entity 'excretion' named entity 'HCQ' named entity 'infection' named entity 'COVID' named entity 'cell surface receptor' named entity 'arachidonic acid' named entity 'infection' named entity 'RNA viruses' named entity 'COVID-19' named entity '4-aminoquinoline' named entity 'antiviral effect' named entity 'randomized clinical trial' named entity 'mitochondrial' named entity 'COVID-19' named entity 'adverse effects' named entity 'clinical trial' named entity 'receptor' named entity 'COVID-19' named entity 'innate immunity'

Faceted Search & Find service v1.13.91 as of Mar 24 2020

Alternative Linked Data Documents: Sponger | ODE Content Formats:

RDF

ODATA

Microdata

About

OpenLink Virtuoso version 07.20.3229 as of Jul 10 2020, on Linux (x86_64-pc-linux-gnu), Single-Server Edition (94 GB total memory)
Data on this page belongs to its respective rights holders.
Virtuoso Faceted Browser Copyright © 2009-2024 OpenLink Software